Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a biotechnology company focused on hereditary angioedema (HAE) and other rare diseases. On this page, you can review BioCryst’s SEC filings alongside AI-generated summaries that help explain complex disclosures in clear language.
Current Reports on Form 8-K are especially important for tracking material events at BioCryst. Recent 8-K filings describe key regulatory milestones, such as U.S. Food and Drug Administration approval of the New Drug Application for an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric HAE patients aged 2 to <12 years. Other 8-Ks cover quarterly financial results, preliminary revenue updates, and guidance for ORLADEYO net revenue, total revenue including RAPIVAB® (peramivir injection), and non-GAAP operating expenses.
Filings also document strategic transactions that shape BioCryst’s business model. One set of 8-Ks details the Stock Purchase Agreement and subsequent closing of the sale of BioCryst Ireland Limited, which held certain assets and rights related to the European ORLADEYO business, along with associated IP license, supply, brand support, transition services, and trademark license agreements. Another 8-K outlines the Agreement and Plan of Merger under which a BioCryst subsidiary will merge with Astria Therapeutics, Inc., including the cash-and-stock merger consideration, closing conditions, and potential delisting of Astria’s stock.
Governance and compensation developments also appear in BioCryst’s filings. Recent 8-Ks describe the planned retirement of the company’s President and Chief Executive Officer, the appointment of a new President and future CEO, the hiring of a new Chief Financial Officer, and related employment and separation agreements. Additional filings report inducement equity grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Alongside these 8-Ks, investors can use this page to access BioCryst’s periodic reports on Forms 10-K and 10-Q (when available), which provide detailed discussions of risk factors, business strategy, and financial statements. Stock Titan’s AI tools highlight key sections of lengthy documents such as annual reports (10-K), quarterly reports (10-Q), and insider transaction filings (Form 4), helping you quickly understand revenue drivers, major agreements, executive changes, and other disclosures that may affect BCRX.
BioCryst Pharmaceuticals reported preliminary, unaudited full-year 2025 net revenue from its hereditary angioedema drug ORLADEYO of $601 million, which the company highlighted as a 37 percent year-over-year increase and above its prior guidance range. The company also discussed non-GAAP views of ORLADEYO sales that exclude European revenue to show comparable growth, noting 36 percent growth for the fourth quarter of 2025 and 43 percent growth for the full year 2025 on this basis. In the same update, BioCryst provided guidance for 2026 ORLADEYO net revenue, total revenue, and operating expenses, and reminded investors of its presentation at the J.P. Morgan Healthcare Conference.
BioCryst Pharmaceuticals' Chief Commercial Officer, Ronald Dullinger, has filed an initial Form 3 reporting his equity holdings in the company. As of 01/01/2026, he beneficially owns 258,372 shares of common stock, which include 206,813 restricted stock units that vest in four equal annual installments starting on each grant’s anniversary.
He also holds several employee stock options to purchase common stock, including grants for 100,000 shares at $2.85 per share expiring in 2029 and 100,000 shares at $8.31 per share expiring in 2030. Additional option awards cover smaller blocks of shares at exercise prices between $6.43 and $11.43, with expiration dates running through 2035. Each option grant vests 25% per year over four years from its grant date.
BioCryst Pharmaceuticals, Inc. is increasing the U.S. wholesale acquisition cost of its hereditary angioedema treatment ORLADEYO (berotralstat) effective January 9, 2026. The price is rising from $44,484.33 to $48,487.92 per 28-day pack of either the 150mg or 110mg capsules. This change applies to the wholesale acquisition cost, which is a list price used in transactions between the company and its buyers in the United States.
BioCryst Pharmaceuticals plans to acquire Astria Therapeutics in a cash-and-stock merger that will make Astria a wholly owned subsidiary. Each share of Astria common stock will be converted into 0.59 of a share of BioCryst common stock plus $8.55 in cash, subject to a cap that limits new BioCryst shares issued in the deal to 19.9% of its pre‑merger shares, with cash increased if the share portion is reduced. Based on recent BioCryst trading prices, this implied about $12.70–$12.76 of value per Astria share around the announcement and mailing dates. Astria’s board unanimously determined the merger is fair and in stockholders’ best interests, obtained a fairness opinion from Evercore, and recommends voting in favor at a January 21, 2026 special meeting. Certain directors, executives and key holders have signed voting agreements supporting the transaction, and BioCryst has arranged a $550 million credit facility to help fund the cash portion.
BioCryst Pharmaceuticals reported an insider equity transaction by an officer serving as President and CCO. On 12/12/2025, 8,181 shares of common stock were withheld by the company at $7.57 per share to cover required tax withholding tied to the vesting of previously granted restricted stock units.
The explanation clarifies that this withholding is for tax purposes and does not represent a sale by the officer. Following this transaction, the officer directly beneficially owns 418,827 shares of BioCryst Pharmaceuticals common stock.
BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes reported two equity transactions in December 2025. On December 12, 8,540 shares of common stock were withheld at $7.57 per share to satisfy required tax withholding tied to vesting restricted stock units, and this is explicitly described as not representing a sale by Barnes.
On December 15, Barnes sold 21,210 shares of common stock at $7.65 per share under a trading plan adopted on August 13, 2025 in accordance with Rule 10b5-1, with the transaction occurring automatically rather than as a discretionary trade. Following these transactions, Barnes directly beneficially owned 315,726 shares of BioCryst common stock.
BioCryst Pharmaceuticals reported that a director who also serves as Chief Executive Officer had 27,368 shares of common stock withheld on December 12, 2025 to satisfy required tax withholding obligations tied to the vesting of previously granted restricted stock units at a price of $7.57 per share.
After this transaction, the insider beneficially owns 1,405,222 shares directly, plus 30,000 shares held in each of two irrevocable trusts for which the insider’s spouse serves as co‑trustee.
The company notes that this tax withholding does not represent an open‑market sale by the reporting person.
BioCryst Pharmaceuticals reports that the U.S. Food and Drug Administration has approved its new drug application for an oral pellet formulation of once-daily ORLADEYO (berotralstat). The approval covers use of this oral pellet formulation as prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to <12 years.
The company has furnished a press release with additional details about this FDA approval as an exhibit to this report.
BioCryst Pharmaceuticals, Inc. (BCRX)9,600 shares of common stock at $7.14 per share in an open market sale, coded "S" for sale. After this transaction, the director beneficially owned 30,642 shares of BioCryst common stock in direct ownership form.
The shares were sold under a pre-arranged trading plan adopted on August 14, 2025 pursuant to Rule 10b5-1. This means the sale occurred automatically according to the plan’s terms rather than as a new discretionary trading decision by the director.
BioCryst Pharmaceuticals (BCRX) reported Q3 2025 results. Revenue was $159.4 million, up from $117.1 million a year ago, driven mainly by product sales of $157.7 million. Net income reached $12.9 million versus a prior-year loss, equal to $0.06 per diluted share. Year-to-date revenue was $468.3 million with net income of $18.0 million.
Operating cash flow for the nine months was $55.4 million. The company ended the quarter with cash and cash equivalents of $84.1 million, short‑term investments of $128.8 million, and long‑term investments of $39.7 million. On the balance sheet, the secured term loan declined to $194.4 million, and royalty financing obligations were $476.8 million in total. Assets and liabilities classified as held for sale were $29.2 million and $26.4 million, respectively.
BioCryst highlighted continued commercialization of ORLADEYO for HAE prevention, with U.S. distribution concentrated through a single specialty pharmacy. Management stated that financial resources as of September 30, 2025 are expected to fund operations for at least the next 12 months. Shares outstanding were 210.5 million as of October 31, 2025.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
